A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
Prostate cancer screening is essential for early detection, especially in high-risk groups like men over 50, African Americans, and those with a family history. Routine screening, including PSA tests ...
CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...
Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results